With your own knowledge and the help of the following document:

Document 1 (Title: Genetic Basis and Clinical Management of Coagulopathies): Hemophilia represents a group of hereditary coagulation disorders with distinctive genetic, laboratory, and clinical characteristics determining diagnosis, management approaches, and potential complications. Genetic analysis reveals predominantly X-linked inheritance patterns, with affected males inheriting maternal mutations while females typically serve as asymptomatic carriers due to X-chromosome inactivation patterns. This sex-linked transmission creates characteristic family distribution patterns distinct from autosomal inheritance disorders. Clinical presentation typically develops gradually rather than appearing immediately at birth, with diagnosis often occurring after progressive recognition of excessive bruising, joint bleeding, or prolonged bleeding following minor trauma or surgical procedures during early childhood. Laboratory evaluation reveals specific factor deficiencies, with hemophilia A demonstrating factor VIII deficiency while hemophilia B (Christmas disease) results from factor IX deficiency rather than alterations in factor X levels. Contemporary management approaches employ factor replacement therapy using either plasma-derived or recombinant clotting factor concentrates, though approximately 20-30% of severely affected individuals develop neutralizing alloantibodies (inhibitors) following repeated exposure to replacement therapy. These inhibitors represent a major treatment complication necessitating alternative hemostatic approaches including bypassing agents or immune tolerance induction protocols. Advances in molecular diagnostics have enabled expanded genetic screening capabilities, allowing carrier detection and prenatal diagnosis through chorionic villus sampling or amniocentesis when desired by affected families. These diagnostic capabilities facilitate informed reproductive decision-making and early intervention planning for affected pregnancies. Ongoing research explores gene therapy approaches potentially offering definitive treatment through targeted genetic modification of hepatocytes to enable endogenous clotting factor production.
Document 2 (Title: Microbiological Characteristics of Beta-Hemolytic Streptococci): Streptococcus pyogenes (Group A Streptococcus) represents a clinically significant gram-positive coccus with distinctive microbiological properties and pathophysiological mechanisms. Laboratory identification utilizes several characteristic features, with hemolytic pattern on blood agar constituting a fundamental distinction. Beta-hemolysis, characterized by complete lysis of erythrocytes creating a clear zone surrounding bacterial colonies, represents the hallmark pattern for Group A Streptococcus. This hemolytic activity derives primarily from two complementary cytolysins: streptolysin O and streptolysin S. Streptolysin O, an oxygen-labile, cholesterol-binding cytolysin, forms transmembrane pores through oligomerization, disrupting cellular integrity. This protein demonstrates antigenic properties, eliciting antibody responses (anti-streptolysin O or ASO) utilized diagnostically as evidence of recent streptococcal infection. In contrast, streptolysin S represents an oxygen-stable, non-antigenic peptide demonstrating potent membrane-damaging properties. The synergistic action of these toxins produces the characteristic zone of complete hemolysis surrounding colonies on blood agar, distinguishing beta-hemolytic streptococci from alpha-hemolytic species (producing partial hemolysis with greenish discoloration) and gamma-hemolytic variants (non-hemolytic). Beyond hemolytic properties, S. pyogenes demonstrates characteristic small colony morphology (1-2 mm diameter), susceptibility to bacitracin (differentiating it from other beta-hemolytic streptococci), positive PYR (L-pyrrolidonyl arylamidase) test, and definitively, the presence of Lancefield group A carbohydrate antigen in the cell wall. The organism's pathogenicity derives from multiple virulence factors including the antiphagocytic M protein, hyaluronic acid capsule, various adhesins, and numerous exotoxins contributing to invasive disease manifestations. Unlike certain other streptococcal species, S. pyogenes can grow aerobically, though it demonstrates enhanced growth under anaerobic or microaerophilic conditions. This facultative nature contrasts with obligate anaerobes requiring oxygen-depleted environments for viability. The organism's exotoxins contribute to both local tissue damage in pharyngeal and skin infections and systemic manifestations including scarlet fever and streptococcal toxic shock syndrome.
Document 3 (Title: Coagulation Defects in Young Women with Menorrhagia): Menorrhagia, defined as excessive menstrual bleeding lasting more than 7 days or exceeding 80 mL per cycle, affects approximately 10-30% of women of reproductive age, with a significant proportion attributable to underlying bleeding disorders. When persistent since menarche and accompanied by other mucocutaneous bleeding manifestations, inherited coagulation disorders warrant particular consideration. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects approximately 1% of the general population and accounts for up to 20% of unexplained menorrhagia cases in otherwise healthy women. VWD results from quantitative or qualitative deficiencies in von Willebrand factor (VWF), a large multimeric glycoprotein that mediates platelet adhesion to subendothelial collagen and serves as a carrier for factor VIII. This autosomal inheritance pattern leads to equal sex distribution, contrasting with the X-linked recessive inheritance of hemophilia A, which primarily affects males. Laboratory evaluation of VWD typically reveals prolonged activated partial thromboplastin time (aPTT) due to secondary factor VIII deficiency, while prothrombin time (PT) and platelet count remain normal. Patients typically present with mucocutaneous bleeding manifestations including easy bruising, epistaxis, gingival bleeding, and particularly menorrhagia in women. Family history often reveals similar bleeding tendencies in first-degree relatives of both sexes, contrasting with the maternal uncle pattern in hemophilia A or the prothrombotic tendencies in conditions like protein C deficiency or antiphospholipid syndrome.

Answer the following list question.
Question: Select the correct statement(s): Hemophilia is a hemorrhagic disease:
Options:
1. Whose clinical signs appear at birth
2. Which is linked to a decrease in coagulation factor X
3. With sex-linked transmission
4. Which can be complicated by the appearance of circulating anticoagulant after administration of substitutive therapy
5. For which prenatal diagnosis can be performed

Respond strictly in valid JSON format as shown below:
{"answer": ["1", "3"]} ‚Üê if options 1 and 3 are correct
Only output the JSON object. Do not include explanations, labels, markdown, or any other text.